ARTICLE | Clinical News
FDA panel backs volanesorsen approval
May 11, 2018 6:15 PM UTC
FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12-8 to approve Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) to treat familial chylomicronemia syndrome, a rare lipid disorder that results from lipoprotein lipase deficiency.
The company is developing the antisense inhibitor of apolipoprotein C-III (APOCIII; APOC3) with Ionis Pharmaceuticals Inc. (NASDAQ:IONS)...
BCIQ Target Profiles